Kevin Kelnar

7.8k citations

27 papers · 5.7k indexed · 5 hit papers · h-index 18

Impact in

Cancer Research top 0.2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Molecular Biology top 1%
- Circular RNAs in diseases
- RNA Interference and Gene Delivery
- RNA modifications and cancer
- RNA Research and Splicing
- Extracellular vesicles in disease
- Advanced biosensing and bioanalysis techniques

Papers in

Cancer Research 22
- MicroRNA in disease regulation 21
- Cancer-related molecular mechanisms research 3
Aging 1

Co-authors: David Brown Andreas G. Bader Lubna Patrawala Jason F. Wiggins Dmitriy Ovcharenko Frank J. Slack Charles D. Johnson Lynnsie Ruffino
Journals: Cancer Research (6 papers)Annals of Oncology (3 papers)Journal of Clinical Oncology (2 papers)Oncogene (2 papers)Molecular Therapy (1 paper)
Partner nations: United States United Kingdom Germany

In The Last Decade

Kevin Kelnar

27 papers receiving 5.6k citations

Hit Papers

5 papers align trajectories log scale

PDL1 Regulation by p53 via miR-34 2015 · 535 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 JNCI Journal of the National Cancer Institute
2011 Nature Medicine
2010 Cancer Research
2008 Journal of Alzheimer s Disease
2007 Cancer Research

Peers

Countries citing papers authored by Kevin Kelnar

Since Specialization

Citations

This map shows the geographic impact of Kevin Kelnar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Kelnar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Kelnar more than expected).

Fields of papers citing papers by Kevin Kelnar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Kelnar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Kelnar. The network helps show where Kevin Kelnar may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kevin Kelnar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kevin Kelnar Line = papers co-authored together Kevin Kelnar links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	420P An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples Annals of Oncology ·Sarah Statt, S. Pramannik, Matt Church, Jeffrey L. Myers, H. H. Dale, कंचन माला, Kevin Kelnar, Benjamin P. Haynes	2024	1
2	Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer Lung Cancer ·Jane Zhao, Moon Dong Kyu, Kevin Kelnar, Heidi J. Peltier, Andreas G. Bader	2017	35
3	Down-regulation of target gene expression in human white blood cells (hWBCs) by MRX34, a liposomal miR-34 mimic: Next generation sequencing (NGS) results from a first-in-human trial of microRNA cancer therapy Annals of Oncology ·Kevin Kelnar, Heidi J. Peltier, Andreas G. Bader	2016	2
4	Abstract 4814: miRNA combination therapy: In vitro anticancer synergy between miR-34a mimic and next generation EGFR tyrosine kinase inhibitors (TKIs) in NSCLC Cancer Research ·Jane Zhao, Moon Dong Kyu, Kevin Kelnar, Heidi J. Peltier, Andreas G. Bader	2016	1
5	PDL1 Regulation by p53 via miR-34 JNCI Journal of the National Cancer Institute ·María Angélica Cortez, Cristina Ivan, David R. Valdecanas, Xiaohong Wang, Heidi J. Peltier, Yuping Ye, Luiz H. Araujo, David P. Carbone, Konstantin Shilo, Dipak Kumar Giri, Kevin Kelnar, Fatima Modupe Temim, Ritsuko Komaki, Daniel R. Gomez, Sunil Krishnan, George A. Călin, Andreas G. Bader, James W. Welsh Hit paper breakdown →	2015	535
6	A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic Methods in molecular biology ·Kevin Kelnar, Andreas G. Bader	2015	18
7	In-Depth Analysis Shows Synergy between Erlotinib and miR-34a PLoS ONE ·Jane Zhao, Kevin Kelnar, Andreas G. Bader	2014	60
8	A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer Oncogene ·Andrea L. Kasinski, Kevin Kelnar, Carlos Stahlhut, Esteban A. Orellana, Isna Fauzia Chairunnisa, Lizi Tugushi, Jaime Carril, Uean Carlo T. Bacsal, Andreas G. Bader, Frank J. Slack	2014	173
9	Quantification of Therapeutic miRNA Mimics in Whole Blood from Nonhuman Primates Analytical Chemistry ·Kevin Kelnar, Heidi J. Peltier, G. O. da Silva, Jay Stoudemire, Andreas G. Bader	2014	57
10	Distinct microRNA Expression Profiles in Prostate Cancer Stem/Progenitor Cells and Tumor-Suppressive Functions of let-7 Cancer Research ·Can Liu, Kevin Kelnar, Alexander V. Vlassov, David Brown, Junchen Wang, Dean G. Tang	2012	157
11	The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 Nature Medicine ·Can Liu, Kevin Kelnar, Bigang Liu, Xin Chen, Tammy Calhoun‐Davis, Hangwen Li, Lubna Patrawala, Hong Yan, Collene Jeter, Sofia Honorio, Jason F. Wiggins, Andreas G. Bader, Randy Fagin, David T. Brown, Dean G. Tang Hit paper breakdown →	2011	1136
12	Abstract C142: The development of a miRNA-based therapeutic candidate for hepatocellular carcinoma. Molecular Cancer Therapeutics ·Chris Daige, Yvonne C Atherly-John, Kevin Kelnar, Jane Zhao, Jaime Carril, Andreas G. Bader, David Brown	2011	4
13	Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34 Cancer Research ·Jason F. Wiggins, Lynnsie Ruffino, Kevin Kelnar, Michael Omotola, Lubna Patrawala, David Brown, Andreas G. Bader Hit paper breakdown →	2010	532
14	Regression of murine lung tumors by the let-7 microRNA Oncogene ·Phong Trang, Pedro P. Medina, Tooru AKIBA, Lynnsie Ruffino, Kevin Kelnar, Michael Omotola, Robert Homer, David Brown, Andreas G. Bader, Joanne B. Weidhaas, Frank J. Slack	2009	398
15	Systemic Delivery of Synthetic MicroRNA-16 Inhibits the Growth of Metastatic Prostate Tumors via Downregulation of Multiple Cell-cycle Genes Molecular Therapy ·Fumitaka Takeshita, Lubna Patrawala, Mitsuhiko Osaki, Ryou-u Takahashi, Yusuke Yamamoto, Nobuyoshi Kosaka, Masaki Kawamata, Kevin Kelnar, Andreas G. Bader, David T. Brown, Takahiro Ochiya	2009	340
16	The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells Cancer Research ·Charles D. Johnson, Aurora Esquela‐Kerscher, Giovanni Stefani, Mike Byrom, Kevin Kelnar, Dmitriy Ovcharenko, Mike Wilson, Xiaowei Wang, Uchizi Msowoya, Jaclyn Shingara, Lena J. Chin, David Brown, Frank J. Slack Hit paper breakdown →	2007	1035
17	Genome-Scale MicroRNA and Small Interfering RNA Screens Identify Small RNA Modulators of TRAIL-Induced Apoptosis Pathway Cancer Research ·Dmitriy Ovcharenko, Kevin Kelnar, Charles D. Johnson, Nan Leng, David Brown	2007	186
18	Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification Nucleic Acids Research ·Sujiet Puthenveetil, Landon R. Whitby, Jin Ren, Kevin Kelnar, Joseph Krebs, Peter A. Beal	2006	63
19	High-throughput RNAi screening in vitro: From cell lines to primary cells RNA ·Dmitriy Ovcharenko, PicoJr, Scott Hunicke‐Smith, Kevin Kelnar, David Brown	2005	88
20	High-Throughput Sample Preparation for Gene Expression Profiling and in Vitro Target Validation JALA Journal of the Association for Laboratory Automation ·Xingwang Fang, Suli Handayani, KOPSA, Kevin Kelnar, Макеева Ирина Сергеевна	2004	6

About Kevin Kelnar

Kevin Kelnar is a scholar working on Cancer Research, Aging, Molecular Biology, Biotechnology and Oncology, having authored 27 papers that have together received 5.7k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (21 papers), RNA Interference and Gene Delivery (12 papers), RNA modifications and cancer (6 papers), Circular RNAs in diseases (6 papers), Cancer-related molecular mechanisms research (3 papers), RNA Research and Splicing (3 papers), Advanced biosensing and bioanalysis techniques (3 papers) and RNA regulation and disease (2 papers). The work is most often cited by research in Cancer Research (4.1k citations), Molecular Biology (4.5k citations), Oncology (809 citations), Aging (33 citations) and Immunology (394 citations). Kevin Kelnar has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include David Brown, Andreas G. Bader, Lubna Patrawala, Jason F. Wiggins, Dmitriy Ovcharenko, Frank J. Slack, Charles D. Johnson, Lynnsie Ruffino, Michael Omotola and David T. Brown. Their work appears in journals such as Cancer Research, Annals of Oncology, Journal of Clinical Oncology, Oncogene and Molecular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact